| 12.35 -0.02 (-0.16%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.02 | 1-year : | 19.09 |
| Resists | First : | 14.57 | Second : | 16.35 |
| Pivot price | 13.07  |
|||
| Supports | First : | 11.71 | Second : | 9.74 |
| MAs | MA(5) : | 12.22  |
MA(20) : | 13.24 |
| MA(100) : | 12.93 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 11.8 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 37 | Low : | 9.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CBIO ] has closed above bottom band by 31.2%. Bollinger Bands are 46.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.55 - 12.61 | 12.61 - 12.66 |
| Low: | 11.79 - 11.87 | 11.87 - 11.94 |
| Close: | 12.23 - 12.36 | 12.36 - 12.46 |
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
Thu, 18 Dec 2025
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
Sat, 13 Dec 2025
BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Thu, 04 Dec 2025
Why Is Crescent Biopharma Stock (CBIO) Up Today? - TipRanks
Thu, 04 Dec 2025
Crescent Biopharma (Nasdaq: CBIO) raises $185M to fund 3 solid tumor programs into 2028 - Stock Titan
Thu, 06 Nov 2025
CRESCENT BIOPHARMA, INC. SEC 10-Q Report - TradingView — Track All Markets
Wed, 05 Nov 2025
Crescent Biopharma (NASDAQ: CBIO) sets November investor talks; webcasts, 90-day replay - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 10.3 (%) |
| Held by Institutions | 103.4 (%) |
| Shares Short | 581 (K) |
| Shares Short P.Month | 578 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 2.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.84 |
| Dividend | 24 |
| Forward Dividend | 0 |
| Dividend Yield | 194.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|